MiR-137 functions as a tumor suppressor in neuroblastoma by downregulating KDM1A

International Journal of Cancer

Volumn 133, Issue 5, 2013, Pages 1064-1073

  Althoff, Kristina ^a   Beckers, Anneleen ^b   Odersky, Andrea ^a   Mestdagh, Pieter ^b   Köster, Johannes ^a,c   Bray, Isabella M ^d,e   Bryan, Kenneth ^d,e   Vandesompele, Jo ^b   Speleman, Frank ^b   Stallings, Raymond L ^d   Schramm, Alexander ^a   Eggert, Angelika ^a   Sprüssel, Annika ^a   Schulte, Johannes H ^a,c  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

^b GHENT UNIVERSITY HOSPITAL   (Belgium)

^c UNIVERSITY OF DUISBURG ESSEN   (Germany)

^d ROYAL COLLEGE OF SURGEONS IN IRELAND   (Ireland)

^e OUR LADY S CHILDREN S HOSPITAL   (Ireland)

Author keywords

epigenetics; LSD1; miR 137; neuroblastoma

Indexed keywords

HISTONE DEMETHYLASE; MESSENGER RNA; MICRORNA; MICRORNA 137; PROTEIN KDM1A; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CANCER PROGNOSIS; CELL PROLIFERATION; CELL STRAIN HEK293; CELL STRAIN SHEP; CELL VIABILITY; CONTROLLED STUDY; DOWN REGULATION; GENE EXPRESSION; GENE FUNCTION; GENE SILENCING; GENE TARGETING; HUMAN; HUMAN CELL; NEUROBLASTOMA; NEUROBLASTOMA CELL; PHENOTYPE; PRIORITY JOURNAL; REPORTER GENE; WESTERN BLOTTING;

EPIGENETICS; LSD1; MIR-137; NEUROBLASTOMA;

CELL LINE, TUMOR; CELL SURVIVAL; DOWN-REGULATION; GENES, TUMOR SUPPRESSOR; HISTONE DEMETHYLASES; HUMANS; MICRORNAS; NEUROBLASTOMA;

EID: 84879230729     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28091     Document Type: Article

References (34)

1. Maris JM, Hogarty MD, Bagatell R, et al. Neuroblastoma. Lancet 2007; 369: 2106-20.
2. Maris JM,. Recent advances in neuroblastoma. N Engl J Med 2010; 362: 2202-11.
3. Park JR, Eggert A, Caron H,. Neuroblastoma: biology, prognosis, and treatment. Hematol Oncol Clin North Am 2010; 24: 65-86.
4. Shimada A, Hirato J, Kuroiwa M, et al. Expression of KIT and PDGFR is associated with a good prognosis in neuroblastoma. Pediatr Blood Cancer 2008; 50: 213-7.
5. Nakagawara A, Arima-Nakagawara M, Scavarda NJ, et al. Association between high levels of expression of the TRK gene and favorable outcome in human neuroblastoma. N Engl J Med 1993; 328: 847-54.
6. Shi Y, Lan F, Matson C, et al. Histone demethylation mediated by the nuclear amine oxidase homolog LSD1. Cell 2004; 119: 941-53.
7. Wang J, Hevi S, Kurash JK, et al. The lysine demethylase LSD1 (KDM1) is required for maintenance of global DNA methylation. Nat Genet 2009; 41: 125-9.
8. Lokken AA, Zeleznik-Le NJ,. Breaking the LSD1/KDM1A addiction: therapeutic targeting of the epigenetic modifier in AML. Cancer Cell 2012; 21: 451-3.
9. Bennani-Baiti IM, Machado I, Llombart-Bosch A, et al. Lysine-specific demethylase 1 (LSD1/KDM1A/AOF2/BHC110) is expressed and is an epigenetic drug target in chondrosarcoma, Ewing's sarcoma, osteosarcoma, and rhabdomyosarcoma. Hum Pathol, in press.
10. Magerl C, Ellinger J, Braunschweig T, et al. H3K4 dimethylation in hepatocellular carcinoma is rare compared with other hepatobiliary and gastrointestinal carcinomas and correlates with expression of the methylase Ash2 and the demethylase LSD1. Hum Pathol 2010; 41: 181-9.
11. Hayami S, Kelly JD, Cho HS, et al. Overexpression of LSD1 contributes to human carcinogenesis through chromatin regulation in various cancers. Int J Cancer 2011; 128: 574-86.
12. Kahl P, Gullotti L, Heukamp LC, et al. Androgen receptor coactivators lysine-specific histone demethylase 1 and four and a half LIM domain protein 2 predict risk of prostate cancer recurrence. Cancer Res 2006; 66: 11341-7.
13. Lim S, Janzer A, Becker A, et al. Lysine-Specific Demethylase 1 (LSD1) is highly expressed in ER-negative breast cancers and a biomarker predicting aggressive biology. Carcinogenesis 2010; 31: 512-20.
14. Schenk T, Chen WC, Gollner S, et al. Inhibition of the LSD1 (KDM1A) demethylase reactivates the all-trans-retinoic acid differentiation pathway in acute myeloid leukemia. Nat Med 2012; 18: 605-11.
15. Schulte JH, Lim S, Schramm A, et al. Lysine-specific demethylase 1 is strongly expressed in poorly differentiated neuroblastoma: implications for therapy. Cancer Res 2009; 69: 2065-71.
16. Calin GA, Croce CM,. MicroRNA-cancer connection: the beginning of a new tale. Cancer Res 2006; 66: 7390-4.
17. Schulte JH, Horn S, Schlierf S, et al. MicroRNAs in the pathogenesis of neuroblastoma. Cancer Lett 2009; 274: 10-5.
18. Garzon R, Calin GA, Croce CM,. MicroRNAs in cancer. Annu Rev Med 2009; 60: 167-79.
19. Schulte JH, Marschall T, Martin M, et al. Deep sequencing reveals differential expression of microRNAs in favorable versus unfavorable neuroblastoma. Nucleic Acids Res 2010; 38: 5919-28.
20. Schulte JH, Schowe B, Mestdagh P, et al. Accurate prediction of neuroblastoma outcome based on miRNA expression profiles. Int J Cancer 2010; 127: 2374-85.
21. Chen Y, Stallings RL,. Differential patterns of MicroRNA expression in neuroblastoma are correlated with prognosis, differentiation, and apoptosis. Cancer Res 2007; 67: 976-83.
22. Molenaar JJ, Domingo-Fernandez R, Ebus ME, et al. LIN28B induces neuroblastoma and enhances MYCN levels via let-7 suppression. Nat Genet 2012; 44: 1199-206.
23. Schulte JH, Horn S, Otto T, et al. MYCN regulates oncogenic MicroRNAs in neuroblastoma. Int J Cancer 2008; 122: 699-704.
24. Mestdagh P, Bostrom AK, Impens F, et al. The miR-17-92 microRNA cluster regulates multiple components of the TGF-beta pathway in neuroblastoma. Mol Cell 2010; 40: 762-73.
25. Bemis LT, Chen R, Amato CM, et al. MicroRNA-137 targets microphthalmia-associated transcription factor in melanoma cell lines. Cancer Res 2008; 68: 1362-8.
26. Kozaki K, Imoto I, Mogi S, et al. Exploration of tumor-suppressive microRNAs silenced by DNA hypermethylation in oral cancer. Cancer Res 2008; 68: 2094-105.
27. Silber J, Lim DA, Petritsch C, et al. miR-124 and miR-137 inhibit proliferation of glioblastoma multiforme cells and induce differentiation of brain tumor stem cells. BMC Med 2008; 6: 14.
28. Sun G, Ye P, Murai K, et al. miR-137 forms a regulatory loop with nuclear receptor TLX and LSD1 in neural stem cells. Nat Commun 2011; 2: 529.
29. Balaguer F, Link A, Lozano JJ, et al. Epigenetic silencing of miR-137 is an early event in colorectal carcinogenesis. Cancer Res 2010; 70: 6609-18.
30. Iorio MV, Croce CM,. MicroRNA dysregulation in cancer: diagnostics, monitoring and therapeutics. A comprehensive review. EMBO Mol Med 2012; 4: 143-59.
31. Tivnan A, Orr WS, Gubala V, et al. Inhibition of neuroblastoma tumor growth by targeted delivery of microRNA-34a using anti-disialoganglioside GD2 coated nanoparticles. PLoS One 2012; 7: e38129.
32. Bray I, Tivnan A, Bryan K, et al. MicroRNA-542-5p as a novel tumor suppressor in neuroblastoma. Cancer Lett 2011; 303: 56-64.
33. Tivnan A, Tracey L, Buckley PG, et al. MicroRNA-34a is a potent tumor suppressor molecule in vivo in neuroblastoma. BMC Cancer 2011; 11: 33.
34. Yang X, Lay F, Han H, et al. Targeting DNA methylation for epigenetic therapy. Trends Pharmacol Sci 2010; 31: 536-46.